NGL Fine-Chem Limited (NGLFINE) Share Price

NSE · Healthcare · Drug Manufacturers - General · ISIN INE887E01022

₹2,721.80-91.60 (-3.26%)

Key metrics

Market Cap
₹1,669 Cr
P/E Ratio
28.22
EPS
95.74
Book Value
532.92
P/B Ratio
5.11
ROE
14.62%
ROCE
13.43%
Debt / Equity
0.37
Net Margin
9.74%
Revenue Growth
36.11%
Profit Growth
127.83%
Dividend Yield
0.06%
52W High
₹3,602.00
52W Low
₹1,271.00
Market Cap Band
small cap
Face Value
5

Ratios computed from the annual results period ending 2026-03-31.

About NGL Fine-Chem Limited

NGL Fine-Chem Limited develops and manufactures veterinary APIs, human APIs, intermediates, and finished dosage forms in India, Europe, the Asia Pacific, the United States, and internationally. The company offers afoxolaner, amitraz, atovaquone, buparvaquone, butaphosphan, carprofen, clorsulon, closantel base, closantel sodium, decoquinate, diminazene diaceturate, febantel, fenbendazole, fluazuron, flumethrin, flunixin meglumine, fluralaner, halquinol, homidium chloride, imidocarb dipropionate, isometamidium chlroide HCl, lotilaner, marbofloxacin, maropitant citrate monohydrate, nitroscanate, nitroxynil, oclacitinib maleate, oxfendazole, parvaquone, permethrin, phenazone, ponazuril, praziquantel, ractopamine HCL, rafoxanide, ricobendazole, r-praziquantel, sarolaner, s-methoprene, toldimfos sodium, toltrazuril, triclabendazole, xylazine base, xylazine HCl, and zilpaterol. It also provides anthelmintics, antiprotozoals, ectoparasiticides, phosphorus supplements, coccidiostats, and non-steroidal anti-inflammatory drugs. In addition, the company offers atovaquone, nitazoxanide, and praziquantel for anti malarial, anti diarrheal, and anthelmintic therapeutic categories. Further, it provides specialty chemicals, such as meglumine, n-ethyl-d-glucamine, n-octyl-d-glucamine, 1,4,7-trimethyl-1,4,7-triazonane, and Mn-MeTACN. It serves companies engages in manufacturing custom pharmaceuticals. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.

Headquarters
Mumbai, India
Employees
498
Promoter Holding
72.49%

The full NGL Fine-Chem Limited analysis

Create a free account to open the complete NGLFINE deep-dive — fourteen tabs of fundamental, technical, institutional and ownership data.

  • 10-year financialsIncome statement, balance sheet and cash flow, year by year.
  • Valuation & fair valueFair-value estimates, quality scores and a value grade.
  • Charts & technicalsCandlestick charts, RSI, MACD, Supertrend and detected patterns.
  • Shareholding historyPromoter, FII, DII and public holdings across every quarter.
  • Ace investor holdingsWhich well-known investors hold it, and how their stake changed.
  • Deals & insider tradesBulk and block deals, insider transactions and mutual-fund holdings.